Stocktoria
Atara Biotherapeutics, Inc. ATRA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2014-10-16
Atara Biotherapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | — |
| R&D expense | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M |
| Operating income | $35.9M | -$83.4M | -$276.0M | -$280.5M | -$340.5M |
| Interest expense | $3.8M | $4.6M | $5.3M | $373,000 | — |
| Income tax | $31,000 | -$12,000 | $15,000 | $12,000 | $46,000 |
| Net income | $32.7M | -$85.4M | -$276.1M | -$228.3M | -$340.1M |
| EPS (diluted) | $2.57 | $-11.41 | $-65.19 | $-2.24 | $-3.63 |
| Operating cash flow | -$50.9M | -$68.7M | -$193.0M | -$270.4M | -$220.5M |
| Free cash flow | -$50.9M | -$69.0M | -$194.2M | -$274.6M | -$231.1M |
| Cash & equivalents | $8.5M | $25.0M | $25.8M | $92.9M | $106.1M |
| Inventory | $0 | $10.7M | $9.7M | $1.6M | $0 |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M | $468.1M |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M | $188.5M |
| Shareholders' equity | -$38.5M | -$97.3M | $99.2M | $126.6M | $279.6M |
Source: SEC EDGAR filings · CIK 0001604464 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.